Last reviewed · How we verify
OROS MPH
OROS MPH is an extended-release formulation of methylphenidate that provides sustained dopamine and norepinephrine reuptake inhibition throughout the day.
OROS MPH is an extended-release formulation of methylphenidate that provides sustained dopamine and norepinephrine reuptake inhibition throughout the day. Used for Attention-deficit/hyperactivity disorder (ADHD) in children and adults.
At a glance
| Generic name | OROS MPH |
|---|---|
| Also known as | Concerta |
| Sponsor | Ortho-McNeil Janssen Scientific Affairs, LLC |
| Drug class | Central nervous system stimulant; dopamine-norepinephrine reuptake inhibitor |
| Target | Dopamine transporter (DAT); norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
Methylphenidate is a central nervous system stimulant that blocks the reuptake of dopamine and norepinephrine at the presynaptic neuron, increasing their availability in the synaptic cleft. The OROS (osmotic release oral system) technology delivers the drug in a controlled, extended manner over approximately 12 hours, providing consistent therapeutic levels and reducing the need for multiple daily doses. This mechanism enhances attention, focus, and impulse control in patients with attention-deficit/hyperactivity disorder.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD) in children and adults
Common side effects
- Insomnia
- Decreased appetite
- Headache
- Nervousness or anxiety
- Abdominal pain
- Tachycardia
- Elevated blood pressure
Key clinical trials
- Benefits of ADHD Treatment in Detained People (PHASE3)
- The Effects of ADHD Medication (TEAM) Study (PHASE4)
- Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) (PHASE4)
- The Study of Efficacy and Safety of Generic Methylphenidate Prolong-released Comparison With Original (NA)
- Pharmacogenetic Studies on Attention Deficit Hyperactivity Disorder
- Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 (PHASE3)
- Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder (PHASE4)
- Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OROS MPH CI brief — competitive landscape report
- OROS MPH updates RSS · CI watch RSS
- Ortho-McNeil Janssen Scientific Affairs, LLC portfolio CI